Literature DB >> 23960893

Regression of aggressive corneal vascularization after photodynamic therapy, subconjunctival Avastin injections and topical cyclosporin-A 1% drops: A case report.

Omar M Kirat1, Hassan A Al-Dhibi.   

Abstract

We describe a case of significant regression of aggressive, deep and superficial corneal vascularization using photodynamic therapy (PDT) with verteporfin, repeated subconjunctival injections of Avastin®, plus topical cyclosporin-A 1% drops. The area of the corneal vascularization was treated with PDT with verteporfin. The subconjunctival space - next to the area of vascularization - was injected with Avastin® (1.25 mg/0.05 ml), immediately after PDT, and then for two more times during the follow-up period. The patient was kept on topical cyclosporin and prednisolone acetate. The outcome was evaluated clinically and photographically for 13 months. Corneal vascularization regressed significantly. No adverse effects were observed, neither locally or systemically. PDT with verteporfin, repeated subconjunctival injections of Avastin®, and topical cyclosporin-A drops appear to be safe and effective in treating aggressive corneal vascularization.

Entities:  

Keywords:  Corneal vascularization; Photodynamic therapy (PDT); Subconjunctival Avastin®; Topical cyclosporin A; Verteporfin

Year:  2010        PMID: 23960893      PMCID: PMC3729826          DOI: 10.1016/j.sjopt.2010.05.002

Source DB:  PubMed          Journal:  Saudi J Ophthalmol        ISSN: 1319-4534


  16 in total

1.  The Boston Ocular Surface Prosthesis as a novel drug delivery system for bevacizumab.

Authors:  Mira Lim; Deborah S Jacobs; Perry Rosenthal; Karen G Carrasquillo
Journal:  Semin Ophthalmol       Date:  2009 May-Jun       Impact factor: 1.975

2.  Corneal neovascularization induced by xenografts or chemical cautery. Inhibition by cyclosporin A.

Authors:  U Benelli; J R Ross; M Nardi; G K Klintworth
Journal:  Invest Ophthalmol Vis Sci       Date:  1997-02       Impact factor: 4.799

3.  [Beta-ray therapy of corneal vascularization after keratoplasty].

Authors:  L Mailáth; M Péter
Journal:  Klin Monbl Augenheilkd       Date:  1972-05       Impact factor: 0.700

Review 4.  Corneal allograft rejection: risk factors, diagnosis, prevention, and treatment.

Authors:  H S Dua; A Azuara-Blanco
Journal:  Indian J Ophthalmol       Date:  1999-03       Impact factor: 1.848

5.  Efficacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium.

Authors:  Mohammad Reza Fallah; Keivan Khosravi; Mohammad Nasser Hashemian; Amir Hoshang Beheshtnezhad; Mohammad Taher Rajabi; Mohsen Gohari
Journal:  Curr Eye Res       Date:  2010-01       Impact factor: 2.424

6.  Fine needle diathermy occlusion of corneal vessels.

Authors:  C T Pillai; H S Dua; P Hossain
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-07       Impact factor: 4.799

7.  Steroid inhibition of limbal blood and lymphatic vascular cell growth.

Authors:  G C Boneham; H B Collin
Journal:  Curr Eye Res       Date:  1995-01       Impact factor: 2.424

8.  Photodynamic therapy of corneal neovascularization with verteporfin.

Authors:  Maurizio Fossarello; Enrico Peiretti; Ignazio Zucca; Antonina Serra
Journal:  Cornea       Date:  2003-07       Impact factor: 2.651

9.  Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization.

Authors:  Yanyan Koenig; Felix Bock; Folkert Horn; Friedrich Kruse; Katja Straub; Claus Cursiefen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-05-05       Impact factor: 3.117

10.  Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2.

Authors:  G L Hernández; O V Volpert; M A Iñiguez; E Lorenzo; S Martínez-Martínez; R Grau; M Fresno; J M Redondo
Journal:  J Exp Med       Date:  2001-03-05       Impact factor: 14.307

View more
  2 in total

Review 1.  Current and emerging therapies for corneal neovascularization.

Authors:  Danial Roshandel; Medi Eslani; Alireza Baradaran-Rafii; Albert Y Cheung; Khaliq Kurji; Sayena Jabbehdari; Alejandra Maiz; Setareh Jalali; Ali R Djalilian; Edward J Holland
Journal:  Ocul Surf       Date:  2018-06-20       Impact factor: 5.033

2.  Comparison of the Therapeutic Efficacies of Topical Rivoceranib and Topical Bevacizumab in a Murine Model of Corneal Neovascularization.

Authors:  Hyeon Jeong Yoon; Je Moon Woo; Yong Sok Ji; Kyung Chul Yoon
Journal:  Medicina (Kaunas)       Date:  2019-11-07       Impact factor: 2.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.